A detailed history of Graham Capital Management, L.P. transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Graham Capital Management, L.P. holds 66,165 shares of ARQT stock, worth $717,228. This represents 0.02% of its overall portfolio holdings.

Number of Shares
66,165
Previous 13,466 391.35%
Holding current value
$717,228
Previous $133,000 362.41%
% of portfolio
0.02%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$7.24 - $12.53 $381,540 - $660,318
52,699 Added 391.35%
66,165 $615,000
Q1 2024

May 15, 2024

SELL
$3.25 - $11.77 $159,090 - $576,153
-48,951 Reduced 78.43%
13,466 $133,000
Q4 2023

Feb 14, 2024

BUY
$1.84 - $4.82 $114,847 - $300,849
62,417 New
62,417 $201,000

Others Institutions Holding ARQT

About Arcutis Biotherapeutics, Inc.


  • Ticker ARQT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 60,187,500
  • Market Cap $652M
  • Description
  • Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...
More about ARQT
Track This Portfolio

Track Graham Capital Management, L.P. Portfolio

Follow Graham Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Graham Capital Management, L.P. with notifications on news.